AquaBounty Technologies, Inc. (AQB) Company Overview

Current identity: a public company in transition

AquaBounty Technologies, Inc. is a Delaware corporation whose common stock remained identified as AQB on the Nasdaq Capital Market in its July 2026 Form 8-K. Historically, AquaBounty developed genetically engineered Atlantic salmon and operated land-based recirculating aquaculture system, or RAS, farms. That description no longer captures the economics of the company. AquaBounty has sold its Indiana grow-out farm, its Canadian farms, and the corporate intellectual property associated with its genetically engineered salmon. It no longer raises salmon and reported no sales or research-and-development expense in the first quarter of 2026.

The company’s present business is therefore best understood as asset realization, financing, and strategic optionality rather than aquaculture production. Its primary remaining operating asset is the partially constructed Ohio Farm Project in Pioneer, Ohio, together with remaining equipment and land. Management has been working with an investment bank to evaluate a possible sale, and a non-binding letter of interest was under consideration in the 2025 annual report.

The remaining economic asset

The regulatory breakthrough created a rare first-mover position

AquaBounty was incorporated in 1991 and obtained exclusive licensing rights in 1996 to a gene construct used to produce faster-growing farm-raised Atlantic salmon. The major strategic milestone came in November 2015, when the U.S. Food and Drug Administration approved the new animal drug application for AquAdvantage Salmon. The FDA’s official AquAdvantage page records that approval and the subsequent facility-specific supplements. In 2018, the Indiana grow-out facility was approved, and commercial-scale U.S. harvests followed in 2021.

That regulatory history mattered because approval of a genetically engineered food animal required extensive safety, effectiveness, containment, and environmental evidence. AquaBounty’s intended model combined proprietary genetics, vertically integrated broodstock and egg production, controlled land-based farming, and proximity to consumers. In strategic terms, it attempted to replace long ocean transport and sea-cage exposure with controlled domestic production.

The strategic unwind was driven by capital intensity, not a simple demand problem

1. 1991–1996
   Company formation and acquisition of exclusive transgene rights established the biotechnology foundation.
2. 2015
   FDA approval validated the product scientifically and created a regulatory first-mover position.
3. 2018–2021
   Indiana approval and the first commercial-scale harvest converted the regulatory asset into an operating business.
4. 2022
   Construction began on a planned 10,000-metric-ton Ohio RAS farm, making scale-up the central capital-allocation bet.
5. June 2023
   Ohio construction stopped after inflation and other factors pushed estimated total cost to $485M–$495M and impaired municipal-bond financing.
6. July 2024
   The Indiana farm and selected Ohio equipment were sold for $9.5M gross, shifting the company from expansion to liquidity preservation.
7. March 2025
   Canadian farms and corporate salmon IP were sold for $5.2M, ending fish-rearing and biotechnology operations.
8. 2025–2026
   The Ohio project was impaired, classified as held for sale, and financed around with common stock, senior notes, and convertible preferred stock.

The history is a case study in the difference between technological validation and scalable project economics. AquaBounty achieved regulatory approval and commercial production, but the Ohio expansion required infrastructure capital far beyond the company’s balance-sheet capacity. Once the planned funding package became unavailable, the strategic logic changed from “build and scale” to “sell assets and preserve optionality.”

There is no recurring operating revenue model today

A conventional “how does the company make money?” answer requires an important qualification: AquaBounty did not report revenue in its continuing operations for the first quarter of 2026, and its former farm activities are presented as discontinued operations. Sales and marketing expense was zero, research and development had already fallen to zero in 2025, and management stated that it no longer incurs sales and marketing costs. This means there is no current customer, pricing, volume, or gross-margin engine to model.

Asset proceeds and financing have replaced product sales

Q1 2026: lower overhead, but continuing cash consumption

The latest full financial package is the quarter ended March 31, 2026. General and administrative expense fell 46% year over year to $0.62M, and operating loss narrowed 47% to $0.62M. Those reductions demonstrate that the company cut the corporate cost base after disposing of its farms. However, other expense of $0.30M, largely related to interest, pushed the loss from continuing operations to $0.93M. Including discontinued operations, net loss was $1.20M, or $0.26 per diluted share.

FY2025 provides the annual baseline

For analysis, Q1 2026 is more representative of the leaner corporate structure than FY2025, but it is not yet a steady-state run rate. Interest and preferred dividends can increase financing costs, transaction expenses can be lumpy, and the timing of an Ohio sale can dominate reported cash flow.

Cost escalation overwhelmed the original financing plan

AquaBounty began construction of the planned 10,000-metric-ton Ohio facility in the first quarter of 2022. By June 2023, it had spent roughly $145M and completed about 30% of the facility. Inflation, labor and material costs, design complexity, contractor dependence, rising interest rates, and other factors lifted the estimated total project cost to a range of $485M–$495M. Management concluded that the project was substantially above prior estimates and beyond what the company could finance, particularly after cost escalation impaired access to the municipal-bond funding that had been central to the plan.

The accounting record shows severe capital destruction

The historical moat was real, but it was sold

AquaBounty once possessed a differentiated bundle: FDA-approved genetically engineered salmon, specialized broodstock, biotechnology expertise, land-based farm operating knowledge, and a vertically integrated production concept. The FDA determined that AquAdvantage Salmon met statutory safety and effectiveness requirements and that the introduced DNA was safe for the fish and the salmon safe to eat. That regulatory validation created barriers that a new entrant could not reproduce quickly.

However, competitive advantage is an owned and monetizable resource, not simply a historical achievement. The Canadian-farm sale included the genetically engineered salmon intellectual property and related trademarks and patents. Because AquaBounty no longer owns the product IP or operates the production system, its former regulatory and biotechnology moat should not be assigned value to AQB unless a contract or retained right is specifically disclosed.

Current market position is defined by alternatives, not salmon share

The balance sheet has negative common equity and limited cash

At March 31, 2026, AquaBounty reported $10.25M of total assets, $12.38M of total liabilities, and a $2.13M stockholders’ deficit. Cash was only $0.44M, while operating cash use during the quarter was $1.02M. The simple cash-runway ratio—cash divided by one quarter of operating cash use—was less than half a quarter before considering transaction costs, interest, or preferred dividends. This is why post-quarter financings were necessary.

Financing preserved runway but increased senior claims

In October 2025, AquaBounty issued $4.0M of unsecured senior notes bearing 18% annual interest and maturing 18 months after closing. In February 2026, it sold 1,269,509 common shares plus pre-funded warrants for 67,706 shares at $0.86 per common share or $0.859 per warrant, producing approximately $1.15M of gross proceeds. In April, the company issued Series A convertible preferred stock, including securities exchanged for indebtedness and a $0.50M cash placement. In June, it sold 109,223 shares of Series B convertible preferred for $2.25M gross under the Series B financing Form 8-K.

For common-stock analysis, the capital structure cannot be reduced to reported debt. Preferred liquidation values, accrued dividends, conversion rights, protective provisions, and potential redemption obligations all affect residual value and governance flexibility. The financing solved an immediate liquidity problem, but at a high contractual cost.

Preferred investors gained substantial voting influence

The 2026 proxy statement reported 5,147,204 common shares and 263,753 Series A preferred shares outstanding on April 7, 2026. The Series A preferred represented 5,275,076 common shares on an as-converted basis, slightly more than the then-outstanding common share count. Common and Series A preferred voted together, with preferred voting on an as-converted basis for the annual-meeting matters.

A later Schedule 13G applied a conversion blocker and reported About Investment and Jiaming Li as beneficial owners of 337,355 common-equivalent shares, or 6.2% of the common class, as of the relevant filing basis. This illustrates why ownership percentages must be read with the security terms: full as-converted voting presentation, beneficial-ownership blockers, and actual issued common shares can produce different percentages without contradiction.

Leadership is concentrated and the board has financing-linked directors

Bensler and Lichti joined the board in October 2025 pursuant to arrangements connected with senior-note financing. That does not by itself imply poor governance, but it shows that financing counterparties have influenced board composition. Preferred protective provisions also require a two-thirds preferred-holder consent for specified actions, including certain senior-security issuances and charter changes. Strategy is therefore shaped by a small management team, an independent board, and investors holding contractual rights senior to common stock.

The opportunity set is narrow but potentially consequential

The most direct opportunity is a sale of the Ohio subsidiary or assets at a value above the net carrying amount after transaction costs and liabilities. A strategic buyer could value the land, permits, construction work, utility access, and remaining equipment differently from an accounting impairment model. Another possibility is a joint venture, recapitalization, or acquisition that uses AquaBounty’s public-company platform. Management’s filings explicitly identify acquisitions, dispositions, mergers, joint ventures, and other strategic transactions as possible paths.

The risks are more immediate. The annual report contains substantial doubt about the company’s ability to continue as a going concern. The Ohio asset may require further impairment or sell below carrying value. Financing may be unavailable or highly dilutive. The 18% senior notes and preferred dividends compound claims, while protective provisions can constrain flexibility. Common shareholders also face listing risk: the 2025 annual report noted periods of negative equity and a market value of listed securities below $5M on March 27, 2026. In July 2026, the board decided not to implement a stockholder-authorized reverse split after concluding that it was not then in shareholders’ best interests.

A conventional operating DCF is not the right starting point

Because AquaBounty has no disclosed recurring operating revenue, a standard revenue-growth-and-margin DCF would create false precision. A more defensible framework begins with adjusted net asset value and scenario analysis. The analyst should estimate the Ohio asset’s net realizable value, subtract liabilities and transaction costs, add or subtract corporate cash burn through closing, and then account for the exact liquidation, dividend, conversion, and redemption terms of each preferred series. Only after a replacement operating business is announced should an enterprise DCF be constructed.

The valuation lesson for students is that enterprise value and common equity value diverge sharply when a company has senior debt, cumulative preferred stock, asset-sale uncertainty, and negative equity. A positive sale price does not automatically imply positive value for common stock; the distribution waterfall matters.

AquaBounty is historically important because it converted a pioneering genetically engineered salmon technology into an FDA-approved commercial product. Yet the current AQB investment and research case is no longer about whether faster-growing salmon can work. The company sold the farms and intellectual property that supported that business after its Ohio scale-up became financially unmanageable.

Today, value depends on a much narrower set of outcomes: monetizing the Ohio Farm Project, controlling corporate cash burn, maintaining public-company and listing functionality, satisfying debt and preferred claims, and selecting a credible future strategy. Cost reductions improved the Q1 2026 operating loss, but $0.44M of quarter-end cash, a $2.13M stockholders’ deficit, 18% senior financing instruments, and a going-concern warning make liquidity and capital structure more important than historical industry potential.